Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study

Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faeezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga, the SHERPA study team
doi: https://doi.org/10.1101/2024.06.07.24306760

Article Information

doi 
https://doi.org/10.1101/2024.06.07.24306760
History 
  • June 11, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Nigel Garrett1,2,*,
  2. Tarylee Reddy3,
  3. Nonhlanhla Yende-Zuma3,
  4. Azwidhwi Takalani4,
  5. Kubashni Woeber5,
  6. Annie Bodenstein6,
  7. Phumeza Jonas6,
  8. Imke Engelbrecht6,
  9. Waasila Jassat7,
  10. Harry Moultrie7,
  11. Debbie Bradshaw8,
  12. Ishen Seocharan3,
  13. Jackline Odhiambo4,
  14. Kentse Khuto4,
  15. Simone I. Richardson9,10,
  16. Millicent A. Omondi11,
  17. Rofhiwa Nesamari11,
  18. Roanne S. Keeton11,
  19. Catherine Riou11,12,
  20. Thandeka Moyo-Gwete9,10,
  21. Craig Innes13,
  22. Zwelethu Zwane13,
  23. Kathy Mngadi13,
  24. William Brumskine13,
  25. Nivashnee Naicker1,
  26. Disebo Potloane1,
  27. Sharlaa Badal-Faesen14,
  28. Steve Innes15,
  29. Shaun Barnabas16,
  30. Johan Lombaard17,
  31. Katherine Gill15,
  32. Maphoshane Nchabeleng18,
  33. Elizma Snyman19,
  34. Friedrich Petrick20,
  35. Elizabeth Spooner21,
  36. Logashvari Naidoo21,
  37. Dishiki Kalonji21,
  38. Vimla Naicker21,
  39. Nishanta Singh21,
  40. Rebone Maboa22,
  41. Pamela Mda23,
  42. Daniel Malan24,
  43. Anusha Nana25,
  44. Mookho Malahleha26,
  45. Philip Kotze27,
  46. Jon J. Allagappen28,
  47. Andreas H. Diacon29,
  48. Gertruida M. Kruger30,
  49. Faeezah Patel31,
  50. Penny L. Moore1,9,10,
  51. Wendy A. Burgers11,12,
  52. Kate Anteyi32,
  53. Brett Leav32,
  54. Linda-Gail Bekker15,
  55. Glenda E Gray33,
  56. Ameena Goga34,35,
  57. the SHERPA study team
  1. 1Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
  2. 2Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
  3. 3Biostatistics Research Unit, South African Medical Research Council (SAMRC), Durban, South Africa
  4. 4Hutchinson Center Research Institute of South Africa, Cape Town, South Africa
  5. 5Grants, Innovation and Product Development Unit, SAMRC, Durban, South Africa
  6. 6Right to Care, Johannesburg, Gauteng, South Africa
  7. 7Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS), Johannesburg, South Africa
  8. 8Burden of Disease Research Unit, SAMRC, Tygerberg, South Africa
  9. 9SAMRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
  10. 10Centre for HIV and STIs, NICD of the NHLS, Johannesburg, South Africa
  11. 11Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa
  12. 12Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa
  13. 13Aurum Institute, Johannesburg, South Africa
  14. 14Clinical HIV Research Unit, Johannesburg, South Africa
  15. 15Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
  16. 16Family Centre for Research with Ubuntu, Tygerberg, South Africa
  17. 17Josha Research, Bloemfontein, South Africa
  18. 18Medunsa Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria, South Africa
  19. 19TASK Eden, George, South Africa
  20. 20Mzansi Ethical Research Centre, Middelburg, South Africa
  21. 21SAMRC Clinical Research Site, Durban South Africa
  22. 22Ndlovu Research Centre, Elandsdoorn, South Africa
  23. 23Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa
  24. 24PHOENIX Pharma, Port Elizabeth, South Africa
  25. 25Perinatal HIV Research Unit, Johannesburg, South Africa
  26. 26Synergy Biomed Research Institute, East London, South Africa
  27. 27Qhakaza Mbokodo Research Clinic, Ladysmith, South Africa
  28. 28Setshaba Research Centre, Soshanguve, South Africa
  29. 29TASK Central, Cape Town, South Africa
  30. 30Ubuntu Clinical Research, Gauteng, South Africa
  31. 31Wits RHI Research Institute, University of Witwatersrand, Johannesburg, South Africa
  32. 32Moderna Inc., Cambridge, MA, USA
  33. 33Office of the President and CEO, SAMRC, Cape Town, South Africa
  34. 34Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa
  35. 35HIV and other Infectious Diseases Research Unit, SAMRC, Durban, South Africa
  1. ↵*Corresponding Author:
    Prof Nigel Garrett; 2nd Floor, Doris Duke Medical Research Institute (Private Bag X7), 719 Umbilo Road, Congela, Durban 4013, South Africa; Email: nigel.garrett{at}caprisa.org; Phone: +27 31 655 0617
Back to top
Posted June 11, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faeezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga, the SHERPA study team
medRxiv 2024.06.07.24306760; doi: https://doi.org/10.1101/2024.06.07.24306760
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area